
PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine Inc. is projected to achieve significant revenue growth, with anticipated risk-adjusted revenues reaching $980 million by 2035, an increase from $32 million in 2030. The company is advancing its PM577 program for Wilson’s Disease towards clinical trials, which presents a favorable commercial opportunity due to its innovative GalNAc-targeting ligand LNP technology and solid data from preclinical models. Additionally, the anticipated positive clinical data from PM359 and the promising developments in the in vivo gene editing franchise are expected to heighten investor interest in Prime Medicine's capabilities and its potential to address high unmet medical needs in genetic therapies.
Bears say
Prime Medicine Inc faces a negative outlook primarily due to significant uncertainties surrounding the regulatory approval process for its gene editing technologies, which could lead to downward revisions in financial projections if products do not gain approval. Additionally, the company's ability to recruit eligible patients for clinical trials may hinder the development of its therapies, further complicating future financial forecasts. Finally, concerns regarding the high potential pricing of Prime's therapies and safety issues associated with gene editing technologies could create substantial barriers to market acceptance and overall success, impacting the company's financial viability.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares